<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Organisms : Viruses : RNA viruses : Flaviviruses : Hepacivirus:" exact="Hepatitis" post="C virus : Biology and life sciences : Microbiology"/>
 <result pre="sciences : Microbiology : Medical microbiology : Microbial pathogens :" exact="Viral" post="pathogens : Flaviviruses : Hepacivirus: Hepatitis C virus :"/>
 <result pre=": Microbial pathogens : Viral pathogens : Flaviviruses : Hepacivirus:" exact="Hepatitis" post="C virus : Medicine and health sciences : Pathology"/>
 <result pre="Pathology and laboratory medicine : Pathogens : Microbial pathogens :" exact="Viral" post="pathogens : Flaviviruses : Hepacivirus: Hepatitis C virus :"/>
 <result pre=": Microbial pathogens : Viral pathogens : Flaviviruses : Hepacivirus:" exact="Hepatitis" post="C virus : Biology and life sciences : Organisms"/>
 <result pre=": Biology and life sciences : Organisms : Viruses :" exact="Viral" post="pathogens : Flaviviruses : Hepacivirus: Hepatitis C virus :"/>
 <result pre="Organisms : Viruses : Viral pathogens : Flaviviruses : Hepacivirus:" exact="Hepatitis" post="C virus : Biology and life sciences : Microbiology"/>
 <result pre="sciences : Microbiology : Medical microbiology : Microbial pathogens :" exact="Viral" post="pathogens : Hepatitis viruses: Hepatitis C virus : Medicine"/>
 <result pre=": Medical microbiology : Microbial pathogens : Viral pathogens :" exact="Hepatitis" post="viruses: Hepatitis C virus : Medicine and health sciences"/>
 <result pre="microbiology : Microbial pathogens : Viral pathogens : Hepatitis viruses:" exact="Hepatitis" post="C virus : Medicine and health sciences : Pathology"/>
 <result pre="Pathology and laboratory medicine : Pathogens : Microbial pathogens :" exact="Viral" post="pathogens : Hepatitis viruses: Hepatitis C virus : Biology"/>
 <result pre="medicine : Pathogens : Microbial pathogens : Viral pathogens :" exact="Hepatitis" post="viruses: Hepatitis C virus : Biology and life sciences"/>
 <result pre="Pathogens : Microbial pathogens : Viral pathogens : Hepatitis viruses:" exact="Hepatitis" post="C virus : Biology and life sciences : Organisms"/>
 <result pre=": Biology and life sciences : Organisms : Viruses :" exact="Viral" post="pathogens : Hepatitis viruses: Hepatitis C virus : Biology"/>
 <result pre="life sciences : Organisms : Viruses : Viral pathogens :" exact="Hepatitis" post="viruses: Hepatitis C virus : Biology and Life Sciences"/>
 <result pre=": Organisms : Viruses : Viral pathogens : Hepatitis viruses:" exact="Hepatitis" post="C virus : Biology and Life Sciences : Immunology"/>
 <result pre=": Liver Diseases: Cirrhosis : Biology and Life Sciences :" exact="Developmental" post="Biology: Fibrosis : Medicine and Health Sciences : Health"/>
 <result pre="Microbiology : Virology: Antivirals : Medicine and health sciences :" exact="Infectious" post="diseases : Viral diseases : Hepatitis: Hepatitis C :"/>
 <result pre="Antivirals : Medicine and health sciences : Infectious diseases :" exact="Viral" post="diseases : Hepatitis: Hepatitis C : Medicine and health"/>
 <result pre="health sciences : Infectious diseases : Viral diseases : Hepatitis:" exact="Hepatitis" post="C : Medicine and health sciences : Gastroenterology and"/>
 <result pre="health sciences : Gastroenterology and hepatology : Liver diseases :" exact="Infectious" post="hepatitis: Hepatitis C Directly observed therapy for HCV with"/>
 <result pre=": Gastroenterology and hepatology : Liver diseases : Infectious hepatitis:" exact="Hepatitis" post="C Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside"/>
 <result pre="inject drugs—First real world data from Austria Glecaprevir/pibrentasvir to cure" exact="hepatitis" post="C in people who inject drugs—Real world data from"/>
 <result pre="source are credited.pone.0229239.pdf Abstract Background Directly acting antivirals (DAA) against" exact="hepatitis" post="C virus (HCV) infection have facilitated sustained virologic response"/>
 <result pre="Background Directly acting antivirals (DAA) against hepatitis C virus (HCV)" exact="infection" post="have facilitated sustained virologic response (SVR) rates &amp;gt;90% in"/>
 <result pre="publication by Plos One. Lay summary Direct acting antivirals cure" exact="hepatitis" post="C in &amp;gt;90% of all patients. People who inject"/>
 <result pre="who inject drugs (PWIDs) represent a relevant at-risk population for" exact="hepatitis" post="C infection and transmission, yet treatment efficacy is often"/>
 <result pre="drugs (PWIDs) represent a relevant at-risk population for hepatitis C" exact="infection" post="and transmission, yet treatment efficacy is often limited by"/>
 <result pre="hepatitis C infection and transmission, yet treatment efficacy is often" exact="limited" post="by poor adherence to clinical visits and drug intake."/>
 <result pre="with high risk of non-adherence to DAA therapy receiving their" exact="hepatitis" post="C medication together with opioid substitution under the direct"/>
 <result pre="supervision of medical staff achieve excellent HCV cure rates. Introduction" exact="Hepatitis" post="C virus (HCV) infection is a leading cause for"/>
 <result pre="achieve excellent HCV cure rates. Introduction Hepatitis C virus (HCV)" exact="infection" post="is a leading cause for cirrhosis, liver-related complications, hepatocellular"/>
 <result pre="(HCV) infection is a leading cause for cirrhosis, liver-related complications," exact="hepatocellular carcinoma" post="(HCC), liver transplantation and death worldwide. HCV treatment at"/>
 <result pre="infection is a leading cause for cirrhosis, liver-related complications, hepatocellular" exact="carcinoma" post="(HCC), liver transplantation and death worldwide. HCV treatment at"/>
 <result pre="death worldwide. HCV treatment at an early stage of the" exact="disease" post="can prevent the progression to cirrhosis and the development"/>
 <result pre="early stage of the disease can prevent the progression to" exact="cirrhosis" post="and the development of liver-related complications, especially in patients"/>
 <result pre="HIV-coinfected patients[9]. The consecutive decrease in HCV-associated HCC and decompensated" exact="cirrhosis" post="lead to a recomposition of liver transplant waitlists with"/>
 <result pre="in HCV-associated HCC and decompensated cirrhosis lead to a recomposition" exact="of liver" post="transplant waitlists with an increased donor organ availability for"/>
 <result pre="increased donor organ availability for patients suffering from other entities" exact="of liver" post="disease[10]. Unfortunately, in many countries of the world access"/>
 <result pre="of the world access to pangenotypic DAA therapy is still" exact="limited" post="by the high treatment costs[11]. The 2015 Agenda for"/>
 <result pre="costs[11]. The 2015 Agenda for Sustainable Development committed to combating" exact="viral hepatitis" post="and the WHO provided models for the elimination of"/>
 <result pre="The 2015 Agenda for Sustainable Development committed to combating viral" exact="hepatitis" post="and the WHO provided models for the elimination of"/>
 <result pre="these patients we used a specifically tailored approach to treat" exact="chronic hepatitis" post="C and compared effectiveness of G/P in this difficult-to-treat"/>
 <result pre="patients we used a specifically tailored approach to treat chronic" exact="hepatitis" post="C and compared effectiveness of G/P in this difficult-to-treat"/>
 <result pre="of a hepatological center. While recent analyses of the German" exact="Hepatitis" post="C-Registry showed promising results concerning the safety and effectiveness"/>
 <result pre="further HCV-microelimination strategies. Patients and methods All DAA-naïve patients with" exact="chronic hepatitis" post="C, 18 years of age or older, who started"/>
 <result pre="HCV-microelimination strategies. Patients and methods All DAA-naïve patients with chronic" exact="hepatitis" post="C, 18 years of age or older, who started"/>
 <result pre="estimated that nearly one third of these patients suffer from" exact="chronic hepatitis" post="C. According to our observations, a considerable percentage of"/>
 <result pre="that nearly one third of these patients suffer from chronic" exact="hepatitis" post="C. According to our observations, a considerable percentage of"/>
 <result pre="Wien–a low-threshold drug treatment facility in Vienna. A second outpatient" exact="hepatitis" post="clinic was established at the Ambulatorium Suchthilfe Wien, where"/>
 <result pre="the serum HCV-RNA level, assessment of HCV GT and stage" exact="of liver" post="fibrosis. In PWIDs on OST treated according to the"/>
 <result pre="serum HCV-RNA level, assessment of HCV GT and stage of" exact="liver fibrosis." post="In PWIDs on OST treated according to the concept"/>
 <result pre="COBAS TaqMan HCV Quantitative Test, version 2.0 (Roche), with a" exact="lower" post="limit of quantification of 15 IU/mL. The HCV GT"/>
 <result pre="Assay (Siemens). Prior to treatment, fibrosis stage was assessed by" exact="transient" post="elastography using the Fibroscan® 502 Touch device with the"/>
 <result pre="for F = 4[29–32]. Only procedures with 10 successful measurements" exact="of liver" post="stiffness with an IQR &amp;lt; 30% were considered reliable."/>
 <result pre="In patients whose LS could not successfully be assessed by" exact="transient" post="elastography, evaluation of fibrosis stage was performed by calculation"/>
 <result pre="for patients without cirrhosis, 12 weeks for patients with compensated" exact="cirrhosis" post="and 16 weeks for treatment-experienced GT3 patients, according to"/>
 <result pre="to label. As recommended by current guidelines, patients with decompensated" exact="cirrhosis" post="were not treated with G/P in order to avoid"/>
 <result pre="received the originally planned number of tablets. Study endpoints The" exact="primary" post="endpoint of this study was SVR as defined by"/>
 <result pre="not lost to FU were included in the mITT analysis." exact="Secondary" post="endpoints included adherence to antiviral therapy in the group"/>
 <result pre="of variable and the presence of normal distribution. In the" exact="primary" post="efficacy analyses, two-sided 95% exact confidence intervals (CI) were"/>
 <result pre="written informed consent from all patients. Results Study population A" exact="total" post="of 145 patients were included in this study; 62.8%"/>
 <result pre="DOT, directly observed therapy; OST, opioid substitution therapy; HIV, human" exact="immunodeficiency" post="virus; IQR, interquartile range; HCV, hepatitis C virus. a"/>
 <result pre="substitution therapy; HIV, human immunodeficiency virus; IQR, interquartile range; HCV," exact="hepatitis" post="C virus. a according to transient elastography (TE; n"/>
 <result pre="IQR, interquartile range; HCV, hepatitis C virus. a according to" exact="transient" post="elastography (TE; n = 135) or APRI (n ="/>
 <result pre="n = 29 (39.2%) reported to be living in a" exact="stable" post="relationship; in addition, relevant psychiatric comorbidity was present in"/>
 <result pre=" Not known 4 (2.8) 4 (5.6) 0 (0.0) Living in" exact="stable" post="relationship [n (%)] 0.069  Yes 65 (44.8) 36 (50.7)"/>
 <result pre="setting; DOT, directly observed therapy; LTFU, lost to follow-up; HCV," exact="hepatitis" post="C virus; GT, genotype. A—All patients (n = 141/145)."/>
 <result pre="end of therapy. B—Patients with advanced fibrosis (n = 21/21)." exact="Advanced" post="fibrosis was defined as F3-F4: ≥9.5 kPa according to"/>
 <result pre="Advanced fibrosis was defined as F3-F4: ≥9.5 kPa according to" exact="transient" post="elastography. C—Patients with HCV GT3 infection (n = 54/56)."/>
 <result pre="≥9.5 kPa according to transient elastography. C—Patients with HCV GT3" exact="infection" post="(n = 54/56). In the DOT-group SVR12 was achieved"/>
 <result pre="12 weeks after cessation of therapy. One patient with GT3" exact="infection" post="and fibrosis stage F0/F1 who was treated for eight"/>
 <result pre="71 weeks after end of therapy. The presumed mode of" exact="infection" post="was needle sharing with a friend. Yet, 28 patients"/>
 <result pre="that some reinfections were missed. Discussion In Austria, treatment of" exact="hepatitis" post="C is only performed at a limited number of"/>
 <result pre="Austria, treatment of hepatitis C is only performed at a" exact="limited" post="number of authorized medical centers. After the stepwise reduction"/>
 <result pre="DAA adherence and improve HCV treatment outcomes in PWIDs on" exact="stable" post="OST with or without ongoing IDU. The Ambulatorium Suchthilfe"/>
 <result pre="Based on these considerations and the available data, PWIDs on" exact="stable" post="OST were included in this study and received directly"/>
 <result pre="PWIDs showed excellent adherence to therapy with only a very" exact="limited" post="number of scheduled DAA-ingestions being missed and, most importantly,"/>
 <result pre="a relevant public health strategy in the attempt to eliminate" exact="hepatitis" post="C in Austria. In accordance with previous studies, SVR"/>
 <result pre="directly observed therapy FU follow-up G/P glecaprevir/pibrentasvir GT genotype HBV" exact="hepatitis" post="B virus HCC hepatocellular carcinoma HCV hepatitis C virus"/>
 <result pre="follow-up G/P glecaprevir/pibrentasvir GT genotype HBV hepatitis B virus HCC" exact="hepatocellular carcinoma" post="HCV hepatitis C virus HIV human immunodeficiency virus IDU"/>
 <result pre="G/P glecaprevir/pibrentasvir GT genotype HBV hepatitis B virus HCC hepatocellular" exact="carcinoma" post="HCV hepatitis C virus HIV human immunodeficiency virus IDU"/>
 <result pre="GT genotype HBV hepatitis B virus HCC hepatocellular carcinoma HCV" exact="hepatitis" post="C virus HIV human immunodeficiency virus IDU injection drug"/>
 <result pre="virus HCC hepatocellular carcinoma HCV hepatitis C virus HIV human" exact="immunodeficiency" post="virus IDU injection drug use IQR interquartile range ITT"/>
 <result pre="Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of" exact="hepatitis" post="C virus infection in 2015: a modelling study. Lancet"/>
 <result pre="HCV Collaborators. Global prevalence and genotype distribution of hepatitis C" exact="virus infection" post="in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–76."/>
 <result pre="Collaborators. Global prevalence and genotype distribution of hepatitis C virus" exact="infection" post="in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–76."/>
 <result pre="3BaumertTF, BergT, LimJK, NelsonDR. Status of Direct-Acting Antiviral Therapy for" exact="Hepatitis" post="C Virus Infection and Remaining Challenges. Gastroenterology. 2019;156(2):431–45. 10.1053/j.gastro.2018.10.02430342035"/>
 <result pre="NelsonDR. Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus" exact="Infection" post="and Remaining Challenges. Gastroenterology. 2019;156(2):431–45. 10.1053/j.gastro.2018.10.02430342035 4CarratF, FontaineH, DorivalC,"/>
 <result pre="DorivalC, SimonyM, DialloA, HezodeC, et al.Clinical outcomes in patients with" exact="chronic hepatitis" post="C after direct-acting antiviral treatment: a prospective cohort study."/>
 <result pre="SimonyM, DialloA, HezodeC, et al.Clinical outcomes in patients with chronic" exact="hepatitis" post="C after direct-acting antiviral treatment: a prospective cohort study."/>
 <result pre="of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for" exact="Hepatitis" post="C Virus Infection?Gastroenterology. 2019;156(2):446–460.e2. 10.1053/j.gastro.2018.10.03330367836 6TampakiM, SavvanisS, KoskinasJ. Impact"/>
 <result pre="of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with" exact="chronic hepatitis" post="C genotype 3 and compensated liver disease. Eur J"/>
 <result pre="ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic" exact="hepatitis" post="C genotype 3 and compensated liver disease. Eur J"/>
 <result pre="in patients with chronic hepatitis C genotype 3 and compensated" exact="liver disease." post="Eur J Gastroenterol Hepatol. 20183;30(3):291–5. 10.1097/MEG.000000000000102729120906 8MandorferM, SchwablP, SteinerS,"/>
 <result pre="response in 100% of HIV/hepatitis C virus-coinfected patients with advanced" exact="liver disease." post="AIDS Lond Engl. 2016424;30(7):1039–47. 9BerenguerJ, Gil-MartinÁ, JarrinI, MorenoA, DominguezL,"/>
 <result pre="JarrinI, MorenoA, DominguezL, MontesM, et al.All-oral direct-acting antiviral therapy against" exact="hepatitis" post="C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in"/>
 <result pre="direct-acting antiviral therapy against hepatitis C virus (HCV) in human" exact="immunodeficiency" post="virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings."/>
 <result pre="10.1016/j.jhep.2018.06.01029940268 11EckmanMH, WardJW, ShermanKE. Cost Effectiveness of Universal Screening for" exact="Hepatitis" post="C Virus Infection in the Era of Direct-Acting, Pangenotypic"/>
 <result pre="ShermanKE. Cost Effectiveness of Universal Screening for Hepatitis C Virus" exact="Infection" post="in the Era of Direct-Acting, Pangenotypic Treatment Regimens. Clin"/>
 <result pre="Pract J Am Gastroenterol Assoc. 201898; 12World Health Organization. Combating" exact="Hepatitis" post="B and C to Reach Elimination by 2030 [Internet]."/>
 <result pre="Sustainable Development [Internet]. 2015. https://www.un.org/ga/search/view_doc.asp?symbol=A/RES/70/1&amp;amp;Lang=E%20(accessed%202%20April%202016) 14collab: European Union HCV Collaborators." exact="Hepatitis" post="C virus prevalence and level of intervention required to"/>
 <result pre="study. Lancet Gastroenterol Hepatol. 2017;2(5):325–36. 10.1016/S2468-1253(17)30045-628397696 15ThomasDL. Global Elimination of" exact="Chronic" post="Hepatitis. LongoDL, editor. N Engl J Med. 2019523;380(21):2041–50. 10.1056/NEJMra181047731116920"/>
 <result pre="Health Organization. Fact sheets on sustainable development goals: health targets." exact="Viral" post="Hepatitis. [Internet]. 2017. http://www.euro.who.int/__data/assets/pdf_file/0003/348222/Fact-sheet-SDG-viral-hepatitis-FINAL-en.pdf?ua=1 17ReibergerT. Chronic hepatitis C: treat"/>
 <result pre="development goals: health targets. Viral Hepatitis. [Internet]. 2017. http://www.euro.who.int/__data/assets/pdf_file/0003/348222/Fact-sheet-SDG-viral-hepatitis-FINAL-en.pdf?ua=1 17ReibergerT." exact="Chronic" post="hepatitis C: treat everyone now or stratify by disease?Minerva"/>
 <result pre="goals: health targets. Viral Hepatitis. [Internet]. 2017. http://www.euro.who.int/__data/assets/pdf_file/0003/348222/Fact-sheet-SDG-viral-hepatitis-FINAL-en.pdf?ua=1 17ReibergerT. Chronic" exact="hepatitis" post="C: treat everyone now or stratify by disease?Minerva Gastroenterol"/>
 <result pre="al.Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with" exact="chronic hepatitis" post="C. J Hepatol. 20193;70(3):379–87. 10.1016/j.jhep.2018.11.01130472321 20FornsX, LeeSS, ValdesJ, LensS,"/>
 <result pre="effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic" exact="hepatitis" post="C. J Hepatol. 20193;70(3):379–87. 10.1016/j.jhep.2018.11.01130472321 20FornsX, LeeSS, ValdesJ, LensS,"/>
 <result pre="LeeSS, ValdesJ, LensS, GhalibR, AguilarH, et al.Glecaprevir plus pibrentasvir for" exact="chronic hepatitis" post="C virus genotype 1, 2, 4, 5, or 6"/>
 <result pre="ValdesJ, LensS, GhalibR, AguilarH, et al.Glecaprevir plus pibrentasvir for chronic" exact="hepatitis" post="C virus genotype 1, 2, 4, 5, or 6"/>
 <result pre="hepatitis C virus genotype 1, 2, 4, 5, or 6" exact="infection" post="in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label,"/>
 <result pre="2, 4, 5, or 6 infection in adults with compensated" exact="cirrhosis" post="(EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet"/>
 <result pre="SatohT, TakahashiK, et al.Glecaprevir and Pibrentasvir for Japanese patients with" exact="chronic hepatitis" post="C genotype 1 or 2 infection: Results from a"/>
 <result pre="TakahashiK, et al.Glecaprevir and Pibrentasvir for Japanese patients with chronic" exact="hepatitis" post="C genotype 1 or 2 infection: Results from a"/>
 <result pre="PolS, AsatryanA, ButiM, ShawD, HézodeC, et al.Glecaprevir/Pibrentasvir in patients with" exact="hepatitis" post="C virus genotype 1 or 4 and past direct-acting"/>
 <result pre="2018;67(4):1253–60. 23WylesD, PoordadF, WangS, AlricL, FelizartaF, KwoPY, et al.Glecaprevir/pibrentasvir for" exact="hepatitis" post="C virus genotype 3 patients with cirrhosis and/or prior"/>
 <result pre="et al.Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with" exact="cirrhosis" post="and/or prior treatment experience: A partially randomized phase 3"/>
 <result pre="et al.Safety and efficacy of glecaprevir/pibrentasvir for the treatment of" exact="chronic hepatitis" post="C in patients aged 65 years or older. PloS"/>
 <result pre="al.Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic" exact="hepatitis" post="C in patients aged 65 years or older. PloS"/>
 <result pre="DoreGJ, WangS, GrebelyJ, ShermanKE, BaumgartenA, et al.Glecaprevir/pibrentasvir in patients with" exact="chronic" post="HCV and recent drug use: An integrated analysis of"/>
 <result pre="GschwantlerM, et al.Safety and efficacy of glecaprevir/pibrentasvir in patients with" exact="chronic hepatitis" post="C genotypes 1–6 receiving opioid substitution therapy. Int J"/>
 <result pre="et al.Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic" exact="hepatitis" post="C genotypes 1–6 receiving opioid substitution therapy. Int J"/>
 <result pre="Glecaprevir/pibrentasvir: Real-world safety, effectiveness, and patient-reported outcomes in the German" exact="Hepatitis" post="C-Registry. Abstract presented at: ILC 2019; 2019 Apr; Vienna,"/>
 <result pre="VergniolJ, FoucherJ, Le BailB, ChanteloupE, HaaserM, et al.Prospective comparison of" exact="transient" post="elastography, Fibrotest, APRI, and liver biopsy for the assessment"/>
 <result pre="APRI, and liver biopsy for the assessment of fibrosis in" exact="chronic hepatitis" post="C. Gastroenterology. 20052;128(2):343–50. 10.1053/j.gastro.2004.11.01815685546 30ChromyD, MandorferM, BucsicsT, SchwablP, BauerD,"/>
 <result pre="and liver biopsy for the assessment of fibrosis in chronic" exact="hepatitis" post="C. Gastroenterology. 20052;128(2):343–50. 10.1053/j.gastro.2004.11.01815685546 30ChromyD, MandorferM, BucsicsT, SchwablP, BauerD,"/>
 <result pre="MandorferM, BucsicsT, SchwablP, BauerD, ScheinerB, et al.Prevalence and Predictors of" exact="Hepatic" post="Steatosis in Patients with HIV/HCV Coinfection and the Impact"/>
 <result pre="BucsicsT, SchwablP, BauerD, ScheinerB, et al.Prevalence and Predictors of Hepatic" exact="Steatosis" post="in Patients with HIV/HCV Coinfection and the Impact of"/>
 <result pre="Care STDs. 20195;33(5):197–206. 10.1089/apc.2018.033331067123 31MoserS, GuticE, SchleicherM, GschwantlerM. Early decrease" exact="of liver" post="stiffness after initiation of antiviral therapy in patients with"/>
 <result pre="liver stiffness after initiation of antiviral therapy in patients with" exact="chronic hepatitis" post="C. Dig Liver Dis. 20168;48(8):970–1. 32SchützA, MoserS, SchwankeC, SchubertR,"/>
 <result pre="stiffness after initiation of antiviral therapy in patients with chronic" exact="hepatitis" post="C. Dig Liver Dis. 20168;48(8):970–1. 32SchützA, MoserS, SchwankeC, SchubertR,"/>
 <result pre="MoserS, SchwankeC, SchubertR, LuhnJ, GuticE, et al.Directly observed therapy of" exact="chronic hepatitis" post="C with ledipasvir/sofosbuvir in people who inject drugs at"/>
 <result pre="SchwankeC, SchubertR, LuhnJ, GuticE, et al.Directly observed therapy of chronic" exact="hepatitis" post="C with ledipasvir/sofosbuvir in people who inject drugs at"/>
 <result pre="inject drugs at risk of nonadherence to direct-acting antivirals. J" exact="Viral" post="Hepat. 20187;25(7):870–3. 10.1111/jvh.1285729316001 33ChromyD, SchwablP, BucsicsT, ScheinerB, StrasslR, MayerF,"/>
 <result pre="20187;25(7):870–3. 10.1111/jvh.1285729316001 33ChromyD, SchwablP, BucsicsT, ScheinerB, StrasslR, MayerF, et al.Non-invasive" exact="liver fibrosis" post="assessment and HCV treatment initiation within a systematic screening"/>
 <result pre="the Study of the Liver. EASL Recommendations on Treatment of" exact="Hepatitis" post="C 2018. J Hepatol. 2018;69(2):461–511. 10.1016/j.jhep.2018.03.02629650333 35GrafC, MückeMM, DultzG,"/>
 <result pre="DultzG, PeifferK-H, KubeschA, IngilizP, et al.Efficacy of Direct-acting Antivirals for" exact="Chronic" post="Hepatitis C Virus Infection in People Who Inject Drugs"/>
 <result pre="PeifferK-H, KubeschA, IngilizP, et al.Efficacy of Direct-acting Antivirals for Chronic" exact="Hepatitis" post="C Virus Infection in People Who Inject Drugs or"/>
 <result pre="et al.Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus" exact="Infection" post="in People Who Inject Drugs or Receive Opioid Substitution"/>
 <result pre="36HajarizadehB, CunninghamEB, ReidH, LawM, DoreGJ, GrebelyJ. Direct-acting antiviral treatment for" exact="hepatitis" post="C among people who use or inject drugs: a"/>
 <result pre="10.1016/S2468-1253(18)30304-230245064 37SchützA, MoserS, MarchartK, HaltmayerH, GschwantlerM. Direct Observed Therapy of" exact="Chronic" post="Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold"/>
 <result pre="37SchützA, MoserS, MarchartK, HaltmayerH, GschwantlerM. Direct Observed Therapy of Chronic" exact="Hepatitis" post="C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug"/>
 <result pre="MahomedA, et al.Efficacy and safety of glecaprevir/pibrentasvir in patients with" exact="chronic hepatitis" post="C virus genotype 5 or 6 infection (ENDURANCE-5,6): an"/>
 <result pre="et al.Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic" exact="hepatitis" post="C virus genotype 5 or 6 infection (ENDURANCE-5,6): an"/>
 <result pre="patients with chronic hepatitis C virus genotype 5 or 6" exact="infection" post="(ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. Lancet Gastroenterol"/>
</results>
